KeyBanc raised the firm’s price target on ResMed (RMD) to $266 from $251 and keeps an Overweight rating on the shares following the Q1 earnings report. KeyBanc was encouraged by the broad ...

RBC Capital raised the firm’s price target on ResMed (RMD) to $232 from $224 and keeps a Sector Perform rating on the shares. The company reported a strong Q1 result with double digit revenue ...

Over the last year, Resmed share price has been traded in a range of 80.58, hitting a high of 260.00, and a low of 179.42.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

As such, the Zacks rating upgrade for ResMed is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future ...

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In addition to Selector's endorsement, analysts at Macquarie retained their buy rating on ResMed shares this week. The broker lifted its price target on the stock to $41.10 following the company's ...

Upgrade your Yahoo Finance plan to get complete details for ResMed Inc. Get advanced tools and insights to navigate the markets.

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, ...